BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
URL: http://rmm.mazums.ac.ir/article-1-100-en.html
, Reza Yarahmadi2 , Amir Tabatabaei2 , Fakhredin Saba1 , Saeid Abroun 3, Amir Atashi1 , Masoud Soleimani1
2- Department of Laboratory Sciences, School of Paramedical Sciences, Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran
3- Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran ,
Myeloproliferative Neoplasm (MPN) are a clonal disorder in hematopoietic stem cells (HSC). MPN is categorized to 8 subclasses, including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocytopenia (ET), primary myelofibrosis (PMF), systematic mastositosis (SM), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), and unclassified myelofibrosis disorders (UMPN). It usually occurs in 5th to 7th decade of life. However, CNL and ET have been observed in children. A lot of mutations have been identified in these disorders that Jak2V617F is the most important mutation. Moreover, several somatic mutations other than JAK2V617F in MPN patients have been reported. Such mutations include MPL, TET2, ASXL1, IDH1, IDH2, CBL, LNK, IKZF, and EZH2 from precursor stem cells. The role of mutations mentioned is not clear in pathogenesis of this disease. Hence, in this study, mutations in different stages of myeloproliferative disorders have been reviewed.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
